A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.

BACKGROUND: Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antiretroviral therapy (ART) reduces morbidity in children infected with the human immunodeficiency virus (HIV). We investigated whether children and adolescents receiving long-term ART in sub-Sahar...

Full description

Bibliographic Details
Main Authors:	Bwakura-Dangarembizi, M, Kendall, L, Bakeera-Kitaka, S, Nahirya-Ntege, P, Keishanyu, R, Nathoo, K, Spyer, M, Kekitiinwa, A, Lutaakome, J, Mhute, T, Kasirye, P, Munderi, P, Musiime, V, Gibb, D, Walker, A, Prendergast, A
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
by: Szubert, A, et al.
Published: (2015)

Opportunities for improving the efficiency of paediatric HIV treatment programmes.
by: Revill, P, et al.
Published: (2015)

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
by: Kasirye, P, et al.
Published: (2012)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe
by: Prendergast, A, et al.
Published: (2019)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
by: Prendergast, A, et al.
Published: (2016)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
by: Bwakura-Dangarembizi, M, et al.
Published: (2015)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
by: Musoke, P, et al.
Published: (2015)

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
by: Picat, M, et al.
Published: (2013)

The expanding role of co-trimoxazole in developing countries.
by: Church, J, et al.
Published: (2015)

The expanding role of co-trimoxazole in developing countries.
by: Church, J, et al.
Published: (2014)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
by: Szubert, A, et al.
Published: (2017)

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial
by: Musiime, V, et al.
Published: (2016)

CO-TRIMOXAZOLE AND BLOOD
by: Fleming, A, et al.
Published: (1974)

The impact of viraemia on inflammatory biomarkers and CD4 cell subpopulations in HIV-infected children in sub-Saharan Africa
by: Prendergast, AJ, et al.
Published: (2021)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
by: Musiime, V, et al.
Published: (2010)

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy
by: Prendergast, A, et al.
Published: (2016)

Letter: Co-trimoxazole and the blood.
by: Fleming, A, et al.
Published: (1974)

Co-trimoxazole prophylaxis in African children with HIV-1 - Reply
by: Gibb, D, et al.
Published: (2005)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
by: Fillekes, Q, et al.
Published: (2014)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
by: Farmer, R, et al.
Published: (2020)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
by: Fillekes, Q, et al.
Published: (2011)

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
by: Musiime, V, et al.
Published: (2014)

Will co-trimoxazole resistance rates ever go down? Resistance rates remain high despite decades of reduced co-trimoxazole consumption
by: Pouwels, K, et al.
Published: (2017)

Acute polyneuropathy possibily associated with co-trimoxazole.
by: Grossman, AB, et al.
Published: (1977)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
by: Hakim, J, et al.
Published: (2017)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
by: Riitho, V, et al.
Published: (2024)

The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa
by: Walker, SM, et al.
Published: (2020)

Late presentation with HIV in Africa: phenotypes, risk and risk stratification in the REALITY trial
by: Siika, A, et al.
Published: (2018)

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
by: Bourke, CD, et al.
Published: (2019)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
by: Kityo, C, et al.
Published: (2018)

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.
by: Chintu, C, et al.
Published: (2004)

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.
by: Kekitiinwa, A, et al.
Published: (2008)

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.
by: Hasse, B, et al.
Published: (2014)

Assessing the outcomes of prolonged cessation-induction and aid-to-cessation trials: floating prolonged abstinence.
by: Aveyard, P, et al.
Published: (2009)